Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abexinostat - Xynomic Pharmaceuticals

Drug Profile

Abexinostat - Xynomic Pharmaceuticals

Alternative Names: CG-781; CRA-024781; PCI-24781; S 78454

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celera Genomics Group
  • Developer GlaxoSmithKline; Janssen Inc; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Pharmacyclics; Servier; University of California at San Francisco; Xynomic Pharmaceuticals
  • Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Rad51 recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
  • Phase I/II Diffuse large B cell lymphoma; Sarcoma
  • No development reported Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 30 Aug 2019 Safety and efficacy data from a phase Ib trial in Solid tumours released by Xynomic Pharmaceuticals
  • 18 Jul 2019 Xynomic Pharmaceuticals plans a phase I/II trial for Non-Hodgkin Lymphoma (Second line therapy or greater) in October 2019 (PO) (NCT04024696)
  • 07 Jun 2019 Phase-I/II clinical trials in Mantle-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03939182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top